Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Investor Presentation (June 2019)
31 slides from Jubilant Pharmova's investor presentation, June 2019
Slide 1: Jubilant Life Sciences Limited Investor Presentation June 2019
Jubilant Life Sciences Limited Investor Presentation June 2019
Slide 2: Disclaimer
Disclaimer Important Disclaimer This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Life Sciences Limited (the “Company”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for
Slide 3: Jubilant Life Sciences Overview
Jubilant Life Sciences Overview Pharmaceuticals Life Science Ingredients Specialty Pharmaceuticals Drug Discovery Radiopharma Specialty Intermediates and Nutritional Solutions Allergy Therapy Products Products CDMO CMO of Sterile Injectables and Non Sterile Products Active Pharmaceutical Ing
Slide 4: Pharmaceuticals Segment
WY jusiant Pharmaceuticals Segment LIFESCIENCES
Slide 5: Evolution of Jubilant Pharma
Evolution of Jubilant Pharma Revenue Contribution(1) JLL acquired Acquired a majority stake in Acquired Draxis Pharma SGX-listed high Completed FY19 API business – Cadista Holdings Inc. Inc. in Canada yield bond acquisition of US$761m Nanjangud, (generics pharmaceutical (manufacturer of sterile offe
Slide 6: Radiopharmaceuticals Business
Radiopharmaceuticals Business Market Size of Industry in North America 3.5 Radiopharmaceuticals Industry in North America is US$2.4bn, expected to grow at CAGR of 6.2% to reach 2.9 3.0 3.2 2.6 2.7 2.2 2.3 2.4 US$3.5bn by 2023 1.9 2.0 Industry (US$bn) Overview (1) Oncology and cardiology diagnosi
Slide 7: Radiopharmacy Business
Radiopharmacy Business # 2 commercial radiopharmacy network(1) in the US, operated under the “Triad Isotope” brand Facilities also include three operational cyclotrons Multi-year agreements with GPOs in place Over 50 radiopharmacies spread across 22 states 750+ employees c.3 mn+ doses delivere
Slide 8: Allergy Therapy Business
Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size Global AIT market stands at US$1.8bn and is expected to grow at CAGR of 8.9% to reach US$2.8bn by 2022 2.6 2.8 2.3 0.5 2.1 Major growth drivers include the increased prevalence of allergic diseases, reduced time to drug 1.7 1.8 2.
Slide 9: Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products
Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products Global Pharmaceutical CMO Industry Size 125 134 109 117 5 5 7 Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a 79 85 92 100 4 5 6 11 5 6 7 12 12 73 6 4 11 11 Industry
Slide 10: API Business
API Business Global Market Size : Synthetic API 149 123 131 129 Global Synthetic API market is US$115bn in 2018 and is expected to grow at a 115 Industry 46 62 51 53 CAGR of 6.7% from 2018 to 2022F to reach US$149bn(1) 48 (US$bn) Overview 53% of outsourced API market is generics(1) 67 72 78 83 8
Slide 11: Solid Dosage Formulations Business
Solid Dosage Formulations Business Global Generics Pharmaceuticals Industry Size by Unbranded Generic Global generics pharmaceutical industry stands at US$111bn US Patent Expiry for Small Molecules Sales(1)(3) and is expected to grow at CAGR of 5.2% to reach US$136bn US$ 72.5 bn by 2023 136 117 12
Slide 12: Life Science Ingredients Segment
Life Science Ingredients Segment 12
Slide 13: Specialty Intermediates & Nutritional Products
Specialty Intermediates & Nutritional Products Global Market Size ($ Mn) : Speciality Chemicals Global Market Size (KT): Vitamin B3 Global specialty chemicals market is USD 1.1 billion in 2018 and is expected to grow at 5.4% to reach USD 1.2 Industry billion in 2022. Overview Global nutrition ma
Slide 14: Life Science Chemicals
Life Science Chemicals Global Market Size (KT): Acetic Global Market Size (KT): Ethyl Anhydride Acetate Global Acetic Anhydride market is 585 KT in 2018 and is expected to Industry grow at 4.2% to reach 662KT in 2022 Overview Global Ethyl Acetate market is 2046 KT in 2018 and is expected to grow
Slide 15: Jubilant Life Sciences – Key Strengths & Strategies
Jubilant Life Sciences – Key Strengths & Strategies 15
Slide 16: Jubilant Life Sciences Key Strengths
Jubilant Life Sciences Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De-risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High-Quality, World –Class, Lo
Slide 17: Leading Market Positions Across Business Lines, with High Barriers to Entry
Leading Market Positions Across Business Lines, with High Barriers To 1 Entry For Specialty Pharmaceuticals Highlights Entry Barriers #3 radiopharmaceuticals manufacturer in the US (1) Extensive regulatory and licensing requirements #2 commercial radiopharmacy network in the US (1) Specialty P
Slide 18: Global Competitive Edge Due to Low Cost and Vertical Integration
Global Competitive Edge Due to Low Cost and Vertical 2 Integration Vertical integration across the value chain enables cost competitive advantage resulting in higher margins Integrated Operations… Life Sciences Ingredients 4 5 6 7 Radiopharmacies Provides direct access to Fine Crop Animal & Human
Slide 19: De-risked Business Model With Diverse Sources of Revenue
3 De-risked Business Model With Diverse Sources of Revenue Presence in niche Specialty businesses that have high barriers to entry Diverse end-use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries Presence across geographic locations ena
Slide 20: Strong Pipeline of Products With Deep R&D Capabilities
4 Strong Pipeline of Products With Deep R&D Capabilities Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma Strong R&D support with a dedicated workforce of more than 500 R&D professionals. Over 852 patents filed till FY19 42 commercial
Slide 21: High-Quality, World-Class, Low Cost Manufacturing Footprint
5 High-Quality, World-Class, Low Cost Manufacturing Footprint Spokane, Washington, USA Roorkee, Uttarakhand Contract manufacturing of Sterile Generics manufacturing injectable and Allergy therapy Gajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and Samlaya, Gujara
Slide 22: Experienced Management Team with High Standards of Corporate Governance
Experienced Management team with high standards of corporate 6 governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 39 industry years in pharma, specialty 33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foods, oil and ga
Slide 23: Demonstrated Financial Track Record with Strong Revenue Growth and Attractive Profitability
Demonstrated Financial Track Record with Strong Revenue Growth and 7 Attractive Profitability Profile Revenue from Operations Total Revenue EBITDA Split Reported EBITDA1 Revenue increased at a CAGR of 12% over FY15-19 and EBITDA 5,826 5,893 5,861 7,518 9,111 732 1,291 1,370 1,558 1,775 increased a
Slide 24: Growth Strategies and Plans
Growth Strategies and Plans Continue to strengthen leadership positions in key business segments 1 Radiopharma: Achieve market leadership by leveraging leadership in existing products and broad distribution network along with expansion of our product portfolio through launch of niche and different
Slide 25: Growth Strategies and Plans
Growth Strategies and Plans 3 Develop a diverse product and service portfolio through differentiated and complex offerings Specialty Pharmaceuticals Focus: Develop differentiated products in the radiopharmaceuticals and specialty injectables segments catering to the North American market CDMO Fo
Slide 26: Appendix
Appendix W JUBILANT LIFESCIENCES
Slide 27: Jubilant Life Science Q4/12M'FY19 – Financial Snapshot
Jubilant Life Science Q4/12M’FY19 – Financial Snapshot Particulars Q4 FY 18 Q4 FY19 YoY Growth 12M FY18 12M FY19 YoY Growth (Rs Crs) (%) (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 2252 2386 6% 7518 9111 21% Pharmaceuticals 1233 1399 13% 3995 5324 33% Life Science Ingredients 968 912
Slide 28: EBITDA after One-off Adjustments
EBITDA after One-off Adjustments Rs Crore % Change % Change S. No. Q4'FY18 Q4'FY19 YoY FY18 FY19 YoY 1 Reported EBITDA 481 351 (27%) 1,558 1,775 14% 2 One-off Adjustments 18 103 485% 90 157 74% 3 Adjusted EBITDA 498 455 (9%) 1,649 1,932 17% 4 Reported EBITDA Margin 21.3% 14.7% 20.7% 19.5% 5 Adjusted
Slide 29: Debt Profile
Debt Profile Particulars 31/03/18 31/03/19 Foreign Currency Loans ($ Mn) ($ Mn) Standalone 9 0 Subsidiaries 358 500 DSCR Total 367 500 8.1 Rupee Loans (Rs. Crs) (Rs. Crs) 3.6 2.3 Standalone 1,007 1,341 Subsidiaries 79 61 Total 1,086 1,402 FY 2017 FY 2018 FY 2019 Gross Debt (Rs. Crs) (Rs. Crs) Standa
Slide 30: Corporate Actions
Corporate Actions In March 2019, Company’s wholly-owned subsidiary Jubilant Pharma Limited, Singapore, issued USD 200 Mn rated unsecured bonds of USD200 million. The Notes bearing interest at 6.00% per annum will Bonds mature in March 2024 In March 2019, the Company fully redeemed the outstandin
Slide 31: Our Vision & Promise
Our Vision & Promise Visit Us: Web Site: www.jubl.com Jubilant Life Sciences Limited, 1-A, Sector 16-A, NOIDA- 201301 UP, India For Investors: Ravi Agrawal Vineet V Mayer Ph: +91-120-436 1002 Ph: +91-120-436 1021 E-mail: ravi.agrawal@jubl.com E-mail: Vineet.mayer@jubl.com 31
Jubilant Life Sciences — Investor Presentation (June 2019) on 6ix